Researchers publish new GSK3 kinase inhibitors

Researchers from the Univ Athens, Station Biologique and Vanderbilt University have published a series of GSK-3 kinase inhibitors that can alter circadian rhythm

Bayer/Onyx initiate new Phase III trial for Nexavar in liver cancer

Bayer and Onyx have announced the initiation of a Phase III study of Nexavar (sorafenib) as an adjuvant therapy for patients with hepatocellular carcinoma

Sunitinib and Sorafenib cause Erythrocytosis, Indicative of class effect?

Researchers report that the development of reversible erythrocytosis is a common side effect following the use of sorafenib and sunitiniband may be a class specific adverse effect with all kinase inhibitors

Sorafenib in Neurofibromatosis/Neurofibromas

The NCI are initiating a phase I trial of Sorafenib in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery

NICE recommends against Avastin, Nexavar, Sutent and Torisel for Kidney Cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has made a preliminary ruling stating that Avastin, Nexavar, Sutent and Torisel  are not  effective enough to warrant their high cost and shouldn’t be prescribed to new patients in Britain.

Sorafenib and Bevacizumab combination therapy increases antitumor activity

Combining Sorafenib and Bevacizumab has been shown to increase antitumur activity in patients with advanced solid tumors, especially those with ovarian cancer.

Nexavar approved for hepatocellular carcinoma in China

Bayer and Onyx have announced that Nexavar has been approved for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer in China

Sorafenib shows efficacy in Phase III hepatocellular carcinoma trial

Sorafenib has been shown to be effective in patients with advanced hepatocellular carcinoma. The median survival and time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.

Genentech halt Avastin/Sutent trial following cases of microangiopathic hemolytic anemia (MAHA)

Genentech have halted its trial of Avastin in combination with Sutent following reports of several cases of microangiopathic hemolytic anemia (MAHA) in patients with solid tumors

Sunitinib shows efficacy in the treatment of Advanced Neuroendocrine Tumors

Sunitinib has shown efficacy in a phase II study of pancreatic neuroendocrine tumor patients.